A retrospective analysis of the active surveillance database showed good tolerability and acceptable safety of remdesivir in coronavirus-infected people admitted to the intensive care unit. As found, the clinical outcome of improvement/cure was 84%, with a greater improvement in people aged < sixty years and on standard low-flow oxygen therapy.

This study was performed to investigate the safety and clinical outcomes of remdesivir therapy for the management of coronavirus disease in India. In this, data was utilized from the active surveillance programme database of hospitalized people with coronavirus infection who were on remdesivir therapy. The study incorporated 2329 people (67.4% males). The most commonly noted comorbidities were hypertension (20.33%) and diabetes (29.69%).

At remdesivir commencement, 97.55% (2272/2329) of people were getting oxygen treatment. Remdesivir was given for five days in 65.38% of people. The most commonly used concomitant medications were steroids (47.9%) and antibiotics (64.9%). Overall, remdesivir showed good tolerability. Notably, 119 adverse events were noted.

The most common were nausea and vomiting in 45.4% and elevated liver enzymes in 14.28% of people. Following data collection, it was found that 6.77% of people died, 84% of people were cured/improved, and 9.16% demonstrated no improvement in their clinical status. When compared to people > sixty years old, people < sixty years old exhibited a considerably reduced mortality rate in the subgroup assessment.

Considering people on oxygen treatment, the improvement/cure rates were remarkably more in people getting standard low-flow oxygen when compared to people getting ventilation (mechanical or non-invasive), or high-flow oxygen therapy. Diabetes high flow oxygen, age > sixty years, non-invasive ventilation and mechanical ventilation, and cardiac disease were the factors linked with increased mortality.